SELLAS Life Sciences Group, Inc. (SLS) Stock Score, Valuation & Financial Research

SELLAS Life Sciences Group, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SLS

SELLAS Life Sciences Group, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 11.63. These figures are a research snapshot, not a buy or sell recommendation.

What SELLAS Life Sciences Group, Inc. does

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company that does not currently generate product revenue. Its business model relies on the development of novel cancer therapeutics, and it anticipates funding operations through capital raises, potential licensing agreements, and milestone payments from partners until it can achieve regulatory approval and commercialization of its product candidates.

Products and services

  • The company is developing a pipeline of cancer immunotherapies, with its lead product candidate being galinpepimut-S (GPS), a cancer vaccine targeting multiple cancer indications.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of its clinical drug candidates; specific supplier names are not disclosed. Source
  • Contract Research Organizations (CROs) — The company relies on third-party contract research organizations to conduct its preclinical studies and clinical trials; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • GenFleet Therapeutics (Shanghai), Inc. — The company has in-licensed a significant portion of its product candidates, including agreements with GenFleet Therapeutics for the development of novel therapeutics. Source

Business strengths to evaluate

  • Development of novel cancer immunotherapies targeting multiple indications Source

Business risks and research considerations

  • History of substantial losses and no current source of product revenue Source
  • Requirement for additional financing to fund operations and clinical development Source
  • Reliance on third parties for manufacturing, clinical trials, and distribution Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SLS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 11.63
Market capitalization:
2.16B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -32.46M
Free cash flow:
USD -28.39M
Cash:
USD 138.44M
Total debt:
USD 737K
EPS:
USD -0.21

What stands out

  • Free cash flow is USD -28.39M, negative for the stored period.
  • The balance sheet shows USD 138.44M of cash versus USD 737K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 137.71M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SLS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SLS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is SLS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for SLS to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of SLS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research SLS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.